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Abstract
Background & Aims—Direct to consumer advertisement (DTCA) and physician promotion of
drugs can influence patient and physician behaviors. We sought to determine the relationship between
promotion of tegaserod and the number of office visits for abdominal pain, constipation, and bloating;
diagnoses of irritable bowel syndrome (IBS); and tegaserod prescriptions.
Methods—We used an Integrated Promotional Services database to estimate tegaserod DTCA and
promotion expenditures, The National Ambulatory/Hospital Medical Care Surveys (1997–2005) to
estimate the number of ambulatory care visits for abdominal pain, constipation, and bloating and
diagnoses of IBS, and IMS Health's National Prescription Audit Plus to estimate the number of
prescriptions. We constructed segmented and multivariate regression models to analyze the data.
Results—In the 3 months immediately following the start of tegaserod DTCA, there was a
significant increase in physician visits (by 1 million; 95% CI 0.5–1.6 million) and IBS diagnoses (by
397,025; 95% CI 3,909–790,141). Subsequently, the trend of visits and IBS diagnoses reduced. In
multivariate analyses that examined the overall relationship of promotion with visits, diagnoses, and
prescriptions, only the relationship between physician promotion and tegaserod prescribing was
significant; every $1 million spent on physician promotion resulted in an additional 4,108
prescriptions (95% CI: 2,526–5,691).
Conclusions—The initial DTCA of tegaserod was associated with a significant, immediate
increase in physician visits and IBS diagnoses. This trend reversed and in multivariate models, neither
DTCA nor physician promotion correlated with visits or diagnoses. Physician promotion (though
not DTCA) correlated with tegaserod prescription volume.
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Throughout much of the world pharmaceutical companies heavily promote prescription drugs
to health care providers.1 In both the United States and New Zealand such drugs are also directly
promoted to consumers.2 In fact, direct to consumer (DTC) advertisement is the most rapidly
growing component of drug promotion in the U.S:3-5 from 1997 through 2006, DTC
advertisement increased from $1.1 billion5 to over $4.8 billion.6
DTC advertisements typically use emotional appeals to urge consumers to consider medical
causes for their symptoms.7, 8 Consequently, consumers gain confidence that makes them more
likely to visit and discuss their health concerns with their physicians.7-10 This may lead to new
diagnoses and new prescriptions,11, 12 especially for those patients who also request the
advertised drug.13, 14 For instance, it has been estimated that each dollar spent on DTC
advertisement yields $4.20 in additional pharmaceutical sales in that class.15
Most DTCA spending is concentrated on a relatively select group of new drugs designed to
treat chronic conditions.5 Irritable bowel syndrome (IBS) and chronic constipation are two
such chronic conditions that are highly prevalent, with each affecting well over 10% of the US
population.16-20 Despite this, only a minority of these individuals seek medical care.19 Reasons
for this low consulting rate likely include a general lack of public awareness, social isolation
due to the stigma associated with bowel dysfunction, and an historic absence of effective
prescription medications.21 However, in July, 2002 tegaserod (Zelnorm, Novartis AG, Basel,
Switzerland) was approved for the treatment of these conditions. Shortly thereafter, tegaserod
was intensely marketed to the public through the “tummies” advertisement campaign which
informed individuals -- often provocatively with images of women with phrases such as “I feel
better” written across their abdomens -- that their abdominal symptoms might be caused by
chronic constipation or IBS and advised them to “ask [their] doctor if Zelnorm is right for
[them].22” In 2004, $122 million was spent on these highly memorable,23 award winning24
DTC advertisements, the 5th most among all prescription drugs.25
In addition to potential consumers, tegaserod was also heavily promoted to physicians: in 2005
professional promotion exceeded $127 million.26 The various forms of physician promotion,
which includes in-office “detailing” by pharmaceutical sales representatives,27-30 provision of
free drug samples,31, 32 and advertisements in professional journals,33 have all been shown to
influence prescribing patterns.34, 35
The heavy DTC advertisement and professional promotion of tegaserod continued until March,
2007 when concern over a small, but statistically significant increase in associated
cardiovascular events led to a complete suspension of any drug marketing.36 Still, these
promotional efforts were likely effective in leading at least some individuals with abdominal
symptoms to see their physician and leading some physicians to diagnose a portion of these
individuals with IBS and/or to prescribe them tegaserod. Considering the high prevalence of
these symptoms, the number of clinic visits, diagnoses, and tegaserod prescriptions may have
increased significantly.
Therefore, the aim of this study was to determine the relationship between tegaserod promotion
and the number of individuals who sought health care for abdominal symptoms, as well as the
diagnoses and treatments that they ultimately received. We hypothesized that the introduction
and promotion of tegaserod correlated with an increase in physician office visits for abdominal
symptoms (e.g., constipation, abdominal pain, and bloating), diagnoses of IBS, and
prescriptions of tegaserod. Additionally, we attempted to parse out the relationships between
various promotional strategies and patient and physician behavior as shown in figure 1.
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To estimate expenditures on DTC advertising and professional promotion of tegaserod we used
data from IMS Health's Integrated Promotional Services data.26 This database estimates total
national expenditures by month and product spent on provider detailing, patient samples,
journal advertising, and DTC advertising (including television, radio, newspaper, consumer
magazine, and billboard advertisements). Expenditures were adjusted to 2004 dollars using the
medical component of the Consumer Price Index (US Department of Labor). The influence of
promotion can be thought of as immediate and cumulative, whereby previous promotional
advertisements may influence current patient behavior. Therefore, we estimated cumulative
monthly spending for DTC advertising and physician detailing by summing current month
spending with discounted spending for the previous 6 months. Based on previous studies we
used an 11% discount rate for DTCA and 0.3% discount rate for detailing.37, 38 These
cumulative monthly spending variables were then aggregated by quarter to match the NAMCS
and NHAMCS data (see below).
To estimate the number of ambulatory care visits for abdominal pain, constipation, and
bloating, as well as diagnoses of IBS in the United States we used administrative data from the
1997-2005 National Ambulatory Medical Care Survey (NAMCS) and the National Hospital
Ambulatory Medical Care Survey (NHAMCS) with sampling weights. The NAMCS is an
annual sample of outpatient visits to office-based community physicians who are principally
engaged in patient care. Visits in this survey are recorded through a multistage clustered
probability sample design based on geographic location, provider specialty, and visits within
individual physician practices. The NHAMCS is an annual sample of ambulatory care services
in hospital emergency and outpatient departments. Because we hypothesized that any effect of
tegaserod DTC advertising and physician promotion would be primarily in non-emergent
settings, emergency department visits were excluded. Visits in this survey are sampled based
on geographic locations, hospitals within these areas, and clinics within the outpatient
departments of these hospitals. In sum, when patient weights are used, these NAMCS and
NHAMCS data can be extrapolated to the over 1 billion visits to physician office and hospital
outpatient departments that occur in the United States each year.39 Both NAMCS and
NHAMCS collect data on the utilization and provision of care. For analysis purposes data were
aggregated by quarter-year. Because tegaserod was initially only promoted to female patients,
all male patients were excluded.
To estimate the volume of tegaserod prescriptions we used data from IMS Health's National
Prescription Audit Plus. National Prescription Audit Plus measures prescriptions of all
pharmaceutical products that are sold from the retail pharmacies including independent and
chain store pharmacies, mass merchandisers and food stores with pharmacies, mail service
pharmacies, and long-term facilities. National Prescription Audit Plus captures more than 70%
of the prescriptions nationally and then applies a proprietary method to estimate the nation-
wide volume.40 Data were aggregated into quarterly estimates.
In addition to the influence of pharmaceutical promotion, physicians' awareness of IBS and
tegaserod may have been influenced by professional publications. Because this may have
affected their diagnoses and prescriptions we determined the number of PubMed citations for
constipation, IBS, and tegaserod per quarter for each year and included these data as covariates
in certain multivariate models (see below).
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We first assessed whether DTC advertisement of tegaserod correlated with a change in the
overall number of physician visits and IBS diagnoses. To do so we used segmented regression
models41 to assess changes in the level (i.e., the value at the beginning of the time interval)
and trend (i.e., the rate of change or slope) in the number of visits for abdominal pain,
constipation, or bloating IBS diagnoses over the 25 quarter periods before tegaserod DTC
advertising compared to the 11 quarter periods during which tegaserod was directly advertised
to consumers. Both regression models included a constant term, a linear time trend (TIME,
quarters 1 to 36), a binary indicator to assess disruption in the trend line following tegaserod
DTC advertising (DTC, quarters 26 to 36), and a linear time trend to assess changes in the slope
of the trend line following tegaserod DTC marketing (DTC-Trend, quarters 26 to 36). The full
regression was modeled as:
From our initial plot, we noticed patterns of seasonality in prescription drug utilization and
expenditures. In other words, observations from a given current quarter were correlated with
observations from the preceding year. Accordingly, we used autoregressive integrated moving
average (ARIMA) models to control for autocorrelation and seasonality in prescription drug
utilization and expenditures in the segmented regression models. Correlograms and partial
correlograms were used to determine the appropriate autoregressive and moving average terms
for each model. All coefficients were deemed significant at p < 0.05.
We next quantified the relationship of various components of DTC and professional promotion
expenditures on the number of physician visits for abdominal pain, constipation, and bloating,
as well as the number of IBS diagnoses. To do so we modeled the amount of promotional
dollars spent in relationship with the sum of quarterly physician visits and IBS diagnoses. For
the latter model we included professional citations of IBS as a covariate. For both models we
used a Poisson distribution in our regressions to control for skew in the distribution of our
count outcome variables. To assess the effect of distributional assumptions on results we also
ran each model using a negative binomial distribution. The level of clinical and statistical
significance of each model was unchanged (results not shown). While we considered each type
of promotion individually, the various forms of promotion directed toward physicians (e.g.,
samples, journal advertising, detailing) were highly correlated. Therefore, in order to avoid
problems with multi-collinearity we also separately examined the relationship between both
DTC advertising and a composite sum of all physician directed promotion with visits and
diagnoses.
Finally, we quantified the relationship between DTC as well as the various components of
professional promotion with the number of tegaserod prescriptions written. To do so we used
an ordinary least squares (OLS) regression, which was chosen based on normality of the
distribution for our prescription variable and for ease in the interpretation of coefficients. For
this model we included professional citations of constipation, IBS, and tegaserod as covariates.
Results
The pattern of quarterly visits for constipation, bloating, and abdominal pain as well as IBS
diagnoses are depicted in Figure 2. In addition, it presents the results from our segmented
regression that depicts changes in the level (i.e., number) and trend of visits and IBS diagnoses
immediately following the start of tegaserod DTC advertising compared with those before
marketing. These results are presented numerically in Table 1. At the beginning of our
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observation period (the first quarter of 1997) there were approximately 3.4 million visits [95%
CI: (2848795, 3887674)] made to physicians for constipation, bloating, and abdominal pain
symptoms and 541,117 IBS diagnoses [95% CI: (316808, 765426)]. From this quarter until
the quarter prior to the start of tegaserod marketing there was a non-significant increase of
17,105 additional physician visits and 2,266 IBS diagnoses per quarter. Immediately following
the start of DTC marketing of tegaserod, there was a significant 1 million visit [95% CI:
(509386, 1644098)] increase in the number of visits made to physicians for constipation,
bloating, and abdominal pain and 397,025 additional diagnoses for IBS. In the subsequent 11
quarters there was a reduction in the trend of visits made to physicians for these symptoms and
IBS diagnoses: patients made 183,933 (β1 + β3 = 17,105 + -201,038) fewer visits to physicians,
and physicians made 64,977 (β1 + β3 = -67,243 + 2,266) fewer IBS diagnoses each quarter.
Results from our Poisson regressions of advertisement spending on physician visits and IBS
diagnoses are shown in Table 2. There was no association between the amount of money spent
on DTC advertising for tegaserod and the number of visits made to physicians for constipation,
bloating, and abdominal pain nor the number of diagnoses made for IBS. However, we did see
evidence of a small, yet statistically significant positive association between physician detailing
and the number of visits for abdominal pain, constipation, and bloating: for every 100 million
dollars spent detailing physicians, we showed a 0.647% [95% CI: (0.184, 1.111)] increase in
visits to physicians for these symptoms. No other physician directed advertisement showed a
significant association in our models. Because in administrative data abdominal pain may be
a non-specific reason for visit, we also ran segmented regression and Poisson regression models
that assessed changes in physician visits for constipation and bloating only. The results did not
meaningfully change.
Figure 3 and table 3 shows results from our regressions of tegaserod advertising spending on
prescriptions for tegaserod. Both DTC and physician directed advertisements were
significantly associated with the amount of prescribing for tegaserod: for every one million
dollars spent advertising tegaserod DTC, an additional 1,796 prescriptions [95% CI: (1041,
2549)] were written. Likewise, for every one million dollars spent on physician directed
promotion (including physician detailing, sampling, and journal advertising) an additional
5,134 prescriptions [95% CI: (4147, 6120)] were written. Among the components of physician
promotion, this association appeared to be predominantly driven by sampling: every one
million dollars spent on sampling of tegaserod was associated with an additional 6,774
prescriptions [95% CI: (5447, 8101)] written. Finally, in a model that simultaneously assessed
the relationship between DTC advertising and physician promotion on prescriptions, only
physician promotion correlated with tegaserod prescribing: for every one million dollars spent
on physician promotion (sampling, detailing, and journal advertisements), there was an
additional 4108 [95% CI: (2526, 5691)] tegaserod prescriptions written. Thus, physician
directed advertising appears to be a more closely tied to tegaserod prescribing than DTC
advertising.
Discussion
In the United States drugs are heavily promoted both directly to consumers and to prescribing
practitioners. This spending – which is nearly double that spent on research and drug
development42 – tends to be most concentrated among a select group of highly prevalent,
chronic conditions, including acid reflux, hyperlipidemia, erectile dysfunction, and IBS and
chronic constipation.25 We sought to determine the relationship between tegaserod promotion
and the number of individuals who sought health care for abdominal symptoms, as well as the
diagnoses and treatments that they ultimately received. We found that the tegaserod DTCA
campaign was associated with an immediate increase in the number of physician visits for
abdominal pain, bloating, and constipation as well as the number of diagnoses of IBS. However,
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this was short lived: over time this trend reversed and overall there was no association between
tegaserod DTCA and the number of visits, IBS diagnoses, nor tegaserod prescriptions. While
professional promotion was not associated with the number of IBS diagnoses, it did correlate
directly with prescription volume.
In the three months following the start of the intensive tegaserod DTCA campaign the number
of physician visits for abdominal pain, bloating, and/or constipation as well as the number of
IBS diagnoses increased substantially (1 million additional visits and 400,000 diagnoses).
Additionally, during this period the proportion of patients who presented with these abdominal
complaints who were subsequently diagnosed with IBS also increased considerably: from 0.13
(2,266/17,105) in the pre-promotion period to 0.40 (397,025/1,000,000) immediately after
promotion. This suggests that beyond increased volume alone, DTCA had an additional link
to physician diagnosis patterns. Nonetheless, over time the rates of visits and diagnoses tapered
off to pre-promotion levels and overall DTCA was not associated with physician visits nor IBS
diagnoses. While there is no simple explanation for this finding, it is possible that the pool of
individuals most susceptible to DTCA responded immediately with visits to their physicians.
In effect, this may have left a group of individuals who were less responsive to later DTC
advertisements.
While we did not specifically assess changes in prescriptions immediately after the start of the
tegaserod DTCA, we were surprised to find that over time DTCA expenditures were not
associated with prescription volumes. These findings counter a broad literature that suggests
DTCA has a strong effect on prescribing behavior.11-15 However, the effects of DTCA may
have decreased over time. For instance, in a recent survey of 68 clinicians following over 1,500
office visits the percentage of patients with DTCA related drug inquiries was substantially
lower (1.7% in public clinic and 7.2% in private practice visits)43 than had been previously
reported (15.8%).44 Thus, it is possible that after years of exposure individuals are now less
responsive to drug advertisements. Additionally, the effects of DTCA may have previously
been over-estimated or overstated, possibly as a result of publication bias. For instance, a
marketing analysis of 391 drugs from 1995-1999 found that while the return on $1 invested in
DTCA for individual drugs was as high as $10.29, the return on investment in DTCA spending
for the “median brand” was not statistically significant.45 Additionally, results of meta-
analyses that include both published and unpublished data suggest that while the effect of
DTCA on prescription volume is typically positive, it is generally weak and is in large part
determined by the characteristics of the advertised drug and its targeted condition.46, 47 Thus,
the weak long-term effect of tegaserod DTCA may relate to the fact that tegaserod was not a
particularly effective medication: a Cochrane review and meta-analysis estimated that for every
17 patients with IBS treated with tegaserod only one responded.48 Similarly, The Oregon Drug
Effectiveness Review Project found that for treating chronic constipation tegaserod was no
better than other less expensive alternatives.49 Thus it is quite plausible that after trying
tegaserod many patients perceived it to be ineffective and therefore discontinued its use.
Unlike DTCA, physician promotion of tegaserod was closely associated with prescription
volume: every $1 million spent on physician promotions was associated with an additional
4,100 prescriptions. Others have also found that compared to DTCA, physician promotion
more strongly influences prescribing.45, 46, 50 Of the components of physician promotion,
sampling produced the greatest positive effect. Likewise, prior studies that utilized physician
surveys,31, 51 administrative databases32 and randomized trials52 have demonstrated that
physicians who distribute samples are in turn more likely to prescribe those medications. Our
finding that journal advertising was inversely associated with prescription volume was
unexpected. However, the wide confidence interval suggests that this estimate was imprecise
and potentially spurious.
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Although a debate of the merits of DTCA and physician promotion is beyond the scope of this
study, both positive and negative implications of tegaserod promotion can be imagined.
Proponents could argue that given significant associated stigma, many patients with IBS and
chronic constipation suffer without seeking health care.19, 21 Thus DTC advertisements may
have been a powerful source of health information that increased patient awareness and
potentially empowered them to discuss their health concerns with their physician.9 Conversely,
opponents may point out that the tegaserod promotion campaign may have resulted in overuse
of a drug that in clinical trials only benefited a select group of patient before adequate
information on the associated increased risk in cardiovascular events was available.53 Although
in a pooled analysis of short term trial data the risk of serious cardiovascular adverse events
for individuals treated with Zelnorm was small (absolute risk increase was 0.09%), when
extrapolated across the population the effect may have been considerable.36
This study had several potential limitations related to the use of administrative data. For
example there was no physician level data and one could imagine a number of potentially
relevant variables (e.g., formulary status, co-payment, drug prices, etc) that were not measured.
54 Additionally the specificity of diagnostic codes was unknown, especially for abdominal
pain. However, when we restricted analyses to changes in constipation and bloating related
visits only the results did not meaningfully change. Second, there were limitations related to
the use of IMS data. While it has been a “gold standard” across research studies of this sort,
some have argued that because IMS does not capture promotional meetings (which annually
total almost $2 billion) nor phase IV “marketing trials” it may underestimate total promotional
expenditures.42 This may have biased either estimate towards or away from the null.
Furthermore, the Food and Drug Administration recognizes the following three types of DTC
advertisements: “reminder advertisements” which call attention to the name of the drug without
making claims on its effectiveness; “help-seeking advertisements” which describe symptoms
and encourage consumers to consult their physician without mentioning the drug's name; and
“product-claims” which reveal both the drug's name and its indication (i.e., “ask your doctor
if Zelnorm is right for you.22”).55 However, the IMS data did not differentiate between these
types of DTC advertisements nor did it assess the content of physician promotional materials.
Third, independent of the tegaserod promotion campaign, general awareness of constipation,
irritable bowel syndrome, and tegaserod likely increased over time. While we attempted to
control for changes in professional awareness, we could not control for similar changes in the
public's awareness. Fourth, although time-series analysis is one of the strongest quasi-
experimental designs for assessing interventions, segmented regression assumes a linear trend
within each segment.41 The addition of subsequent time points would have helped to stabilize
linear trends.
In conclusion, the initial DTCA of tegaserod was associated with a significant, immediate
increase in physician visits for abdominal pain, constipation, and bloating as well as IBS
diagnoses. However, over time this trend reversed and in multivariate models neither DTCA
nor physician promotion had any overall relationship with visits or diagnoses. Physician
promotion (especially detailing) was significantly correlated with tegaserod prescription
volume.
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Figure 1. Conceptual Model
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Figure 2. Gastroenterological Related Diagnoses and Office Visits
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Figure 3. Monthly tegaserod Advertising and Prescribing Patterns
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Physician visits for constipation, Bloating, and abdominal Paining
Baseline Visits (β0) 3,368,235*** (2,848,795;3,887,674)
Trend (β1) 17,105 (-23,128; 57,338)
dtc (β2) 1,076,742*** (509,386; 1,644,098)
DTC Trend (β3) -201,038*** (-281,970: -120,106)
Physician diagnoses for Irritable Bowel Syndrome
Baseline Diagnoses (β0) 541,117*** (316,808; 765,426)
Trend (β1) 2,266 (-10,854; 15,386)
DTC (β2) 397,025* (3,909; 790,141)
DTC Trend (β3) -67,243*** (-104,577; -29,908)
*
Significant at p < 0.05
**
Significant at p < 0.01
***
Significant at p < 0.001
Baseline: number of visits or diagnoses during the first quarter of 1997
Trend (Bl): number of additional visits to physicians or IBS diagnoses per quarter prior to the start of the DTC marketing campaign
DTC (B2): number of additional visits to physicians or IBS diagnoses during the first quarter of the marketing campaign
DTC trend: number of visits or diagnoses per quarter following the start of the DTC marketing campaign
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Table 2
Predicted Advertising Effect on Quarterly Physician Visits (Model 2A) and IBS Diagnoses (Model 2B)
Coefficient 95% CI
Physician Visits for Constipation, Bloating, and Abdominal Pain1
DTC Advertising -0.00027 (-0.00202, 0.00149)
Physician Directed Advertising 0.00057 (-0.00221, 0.00335)
Physician Detailing 0.00647** (0.00184, 0.01111)
Sampling -0.00190 (-0.00625, 0.00245)
Journal Advertising 0.07974 (-0.02500, 0.18448)
IBS Diagnoses1
DTC Advertising -0.00014 (-0.00438, 0.00410)
Physician Directed Advertising -0.00026 (-0.00640, 0.00588)
Physician Detailing 0.00620 (-0.00524, 0.01764)
Sampling -0.00290 (-0.01331, 0.00752)
Journal Advertising 0.05786 (-0.19806, 0.31378)
1
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Table 3
Ordinary Least Squared Regression of Marketing on Monthly tegaserod Prescribing (Model 3)
Coefficient 95% CI
Univariate Model of Each Individual Predictor
DTC Advertising 1,796*** (1,041; 2,549)
Physician Directed Advertising 5.134*** (4,147; 6,120)
Physician Detailing 19.09 (-5.850; 5,888)
Sampling 6,774*** (5,447; 8,101)
Journal Advertising -195,537*** (-235,363;-155,710)
Multivariate Model Combining All Predictors
Intercept -68,124** (-105,112;-31,136)
DTC Advertising 192 (-734; 1,118)
Physician Directed Advertising 4,108*** (2,526; 5,691)
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